High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations.
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2024024962
Abstract: This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no… read more here.
Keywords: acid therapy; patients tet2; high dose; dose ascorbic ... See more keywords